Loading...

Inovalon Holdings

DB:IOV
Snowflake Description

Reasonable growth potential and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IOV
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Inovalon Holdings, Inc., a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print Invest
IOV Share Price and Events
Price Volatility
IOV
Industry
5yr Volatility vs Market

Value

 Is Inovalon Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Inovalon Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Inovalon Holdings.

DB:IOV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IOV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.601 (1 + (1- 21%) (59.62%))
0.884
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.884 * 9.46%)
8.9%

Discounted Cash Flow Calculation for DB:IOV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Inovalon Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:IOV DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) 68.00 73.79 80.07 86.89 94.29
Source Analyst x3 Est @ 8.51% Est @ 8.51% Est @ 8.51% Est @ 8.51%
Present Value
Discounted (@ 8.9%)
62.44 62.22 62.00 61.78 61.56
Present value of next 5 years cash flows $310.01
DB:IOV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $94.29 × (1 + 0.54%) ÷ (8.9% – 0.54%)
$1,134.32
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $1,134.32 ÷ (1 + 8.9%)5
$740.65
DB:IOV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $310.01 + $740.65
$1,050.66
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,050.66 / 152.66
$6.04
DB:IOV Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:IOV represents 0.87793x of NasdaqGS:INOV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87793x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 6.88 x 0.87793
€6.04
Value per share (EUR) From above. €6.04
Current discount Discount to share price of €9.35
= -1 x (€9.35 - €6.04) / €6.04
-54.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Inovalon Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Inovalon Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Inovalon Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IOV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-0.02
NasdaqGS:INOV Share Price ** NasdaqGS (2018-09-21) in USD $10.65
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 21.39x
Germany Market PE Ratio Median Figure of 429 Publicly-Listed Companies 19.19x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Inovalon Holdings.

DB:IOV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:INOV Share Price ÷ EPS (both in USD)

= 10.65 ÷ -0.02

-634.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovalon Holdings is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Inovalon Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Inovalon Holdings's expected growth come at a high price?
Raw Data
DB:IOV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -634.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
125%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.28x
Germany Market PEG Ratio Median Figure of 274 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

DB:IOV PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -634.27x ÷ 125%

-5.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovalon Holdings is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Inovalon Holdings's assets?
Raw Data
DB:IOV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $4.55
NasdaqGS:INOV Share Price * NasdaqGS (2018-09-21) in USD $10.65
Germany Healthcare Services Industry PB Ratio Median Figure of 8 Publicly-Listed Healthcare Services Companies 2.61x
Germany Market PB Ratio Median Figure of 580 Publicly-Listed Companies 2.03x
DB:IOV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:INOV Share Price ÷ Book Value per Share (both in USD)

= 10.65 ÷ 4.55

2.34x

* Primary Listing of Inovalon Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovalon Holdings is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Inovalon Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Inovalon Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Inovalon Holdings expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
125%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Inovalon Holdings expected to grow at an attractive rate?
  • Inovalon Holdings's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Inovalon Holdings's earnings growth is expected to exceed the Germany market average.
  • Inovalon Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IOV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IOV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 125%
DB:IOV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 11.8%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 7.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 5.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IOV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IOV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 689 46 3
2019-12-31 647 134 11 7
2018-12-31 570 91 -22 7
DB:IOV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 476 77 -2
2018-03-31 434 102 14
2017-12-31 449 98 34
2017-09-30 431 105 18
2017-06-30 420 102 17
2017-03-31 433 81 28
2016-12-31 428 93 27
2016-09-30 452 92 42
2016-06-30 453 80 45
2016-03-31 446 81 55
2015-12-31 437 68 66
2015-09-30 407 80 64

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Inovalon Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Inovalon Holdings's revenue is expected to grow by 11.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IOV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Inovalon Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IOV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.31 0.31 0.31 1.00
2019-12-31 0.08 0.22 -0.03 3.00
2018-12-31 -0.15 -0.09 -0.21 3.00
DB:IOV Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -0.02
2018-03-31 0.10
2017-12-31 0.24
2017-09-30 0.12
2017-06-30 0.12
2017-03-31 0.19
2016-12-31 0.18
2016-09-30 0.28
2016-06-30 0.30
2016-03-31 0.36
2015-12-31 0.45
2015-09-30 0.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Inovalon Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Inovalon Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Inovalon Holdings has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Inovalon Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Inovalon Holdings's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Inovalon Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Inovalon Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Inovalon Holdings's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Inovalon Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Inovalon Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IOV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 476.03 -2.39 218.85 26.28
2018-03-31 433.81 13.99 201.35 26.02
2017-12-31 449.36 33.83 190.69 27.38
2017-09-30 430.83 17.54 168.27 28.95
2017-06-30 419.99 17.32 169.51 30.58
2017-03-31 433.24 28.16 162.37 31.00
2016-12-31 427.59 26.94 162.05 29.15
2016-09-30 452.06 42.32 159.36 26.18
2016-06-30 452.50 44.66 152.21 25.06
2016-03-31 446.30 54.61 142.33 22.85
2015-12-31 437.27 66.01 128.21 22.33
2015-09-30 406.63 63.50 117.37 22.95
2015-06-30 387.16 67.06 105.05 22.85
2015-03-31 370.50 64.55 100.29 22.49
2014-12-31 361.54 65.35 95.45 23.13
2014-09-30 336.16 57.59 90.00 22.40
2014-06-30 325.17 53.40 86.84 21.46
2014-03-31 302.34 38.52 85.87 21.78
2013-12-31 295.80 32.72 86.59 21.19
2012-12-31 300.28 55.16 79.45 15.50
2011-12-31 239.69 24.93 68.72 14.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Inovalon Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Inovalon Holdings used its assets less efficiently than the DE Healthcare Services industry average last year based on Return on Assets.
  • It is difficult to establish if Inovalon Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Inovalon Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Inovalon Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Inovalon Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Inovalon Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Inovalon Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Inovalon Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Inovalon Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Inovalon Holdings Company Filings, last reported 2 months ago.

DB:IOV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 693.92 969.40 83.68
2018-03-31 631.76 241.95 450.28
2017-12-31 642.77 248.70 476.23
2017-09-30 652.09 243.99 525.66
2017-06-30 657.81 251.52 531.55
2017-03-31 665.40 259.05 533.31
2016-12-31 683.58 266.58 573.00
2016-09-30 728.62 270.35 713.32
2016-06-30 769.81 274.13 743.88
2016-03-31 750.61 277.92 738.48
2015-12-31 739.16 281.66 728.16
2015-09-30 716.90 285.36 714.09
2015-06-30 673.17 290.39 796.99
2015-03-31 646.36 295.24 793.11
2014-12-31 -8.22 300.27 162.57
2014-09-30 -23.36 300.30 131.95
2014-06-30 261.73 0.33 120.08
2014-03-31 231.73 0.41 110.59
2013-12-31 231.73 0.41 110.59
2012-12-31 236.83 0.29 106.36
2011-12-31
  • Inovalon Holdings's level of debt (139.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.1% vs 139.7% today).
  • Debt is not well covered by operating cash flow (7.9%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 0.7x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Inovalon Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Inovalon Holdings has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Inovalon Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Inovalon Holdings dividends.
If you bought €2,000 of Inovalon Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Inovalon Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Inovalon Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IOV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 2.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IOV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Inovalon Holdings has not reported any payouts.
  • Unable to verify if Inovalon Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Inovalon Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Inovalon Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Inovalon Holdings's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Inovalon Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Inovalon Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Inovalon Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Inovalon Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Keith Dunleavy, image provided by Google.
Keith Dunleavy
COMPENSATION $210,269
AGE 49
TENURE AS CEO 4.7 years
CEO Bio

Dr. Keith R. Dunleavy, M.D., has been the Chairman of Inovalon Holdings, Inc. since 2006 and its Chief Executive Officer since 1998. Dr. Dunleavy is responsible for the overall execution of Inovalon Holdings, Inc.’s business plan, expansion of strategic relationships and the identification and realization of Company product strategy and vision. He served as the President of Inovalon, Inc. until May 19, 2014. During his tenure at Inovalon, He has worked extensively with a wide array and number of healthcare organizations, regulatory and oversight bodies and technology companies examining the growing role of data within healthcare and its ability to drive meaningful insight and improvement for its constituents. Driven by a vision of data's ability to drive insight and improvement in healthcare, He led Inovalon from its origins to its current industry-leading position leveraging advanced, cloud-based analytical and data-driven intervention platforms. Prior to organizing predecessor companies of Inovalon, Dr. Dunleavy worked in areas of management consulting designed to leverage the benefits of multidisciplinary personnel teams with prowess within the basic sciences, software technology, business strategy, finance and operational scaling. In this role, he has served in a wide range of design, strategy and management positions for an array of basic science research, corporate development initiatives and private equity projects. He has been a Director of Inovalon Holdings, Inc. since 2006. He serves as a Director of Board of Overseers at Dartmouth Medical School. He has authored or co-authored a number of scientific journal articles, abstracts and proprietary research papers and has presented his work and materials at multiple national and international conferences. He received a Bachelor’s degree in Biology modified with Engineering with High Honors from Dartmouth College where his thesis work focused on applications of computer-simulated artificial human cerebellar functional units. Dr. Dunleavy earned his doctorate in medicine from Harvard Medical School, completed his medical residency at The Johns Hopkins Hospital in Baltimore, Maryland, practiced and was Board Certified in Internal Medicine.

CEO Compensation
  • Keith's compensation has been consistent with company performance over the past year.
  • Keith's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Inovalon Holdings management team in years:

2.7
Average Tenure
46
Average Age
  • The tenure for the Inovalon Holdings management team is about average.
Management Team

Keith Dunleavy

TITLE
Chairman & CEO
COMPENSATION
$210K
AGE
49
TENURE
4.7 yrs

Bob Wychulis

TITLE
President
COMPENSATION
$6M
AGE
63
TENURE
4.3 yrs

Mike Burgin

TITLE
Chief Product Officer
COMPENSATION
$4M
AGE
44
TENURE
0.8 yrs

Jonathan Boldt

TITLE
Interim Chief Financial Officer
AGE
33
TENURE
0.5 yrs

Jason Capitel

TITLE
Chief Operating Officer
AGE
46
TENURE
0.4 yrs

George Price

TITLE
Investor Relations

Kim Collins

TITLE
Senior Vice President of Corporate Marketing & Communications

Eric Sullivan

TITLE
Senior Vice President of Innovation & Data Strategies

John Spitz

TITLE
Senior Vice President of Business Solutions & Sales
TENURE
2.9 yrs

Angel Oddo

TITLE
Senior Vice President of Quality Products & Solutions
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the Inovalon Holdings board of directors in years:

6.7
Average Tenure
65
Average Age
  • The tenure for the Inovalon Holdings board of directors is about average.
Board of Directors

Denise Fletcher

TITLE
Director
COMPENSATION
$185K
AGE
69
TENURE
6.7 yrs

Keith Dunleavy

TITLE
Chairman & CEO
COMPENSATION
$210K
AGE
49
TENURE
12.7 yrs

Lee Roberts

TITLE
Director
COMPENSATION
$185K
AGE
65
TENURE
6.7 yrs

Bill Teuber

TITLE
Director
COMPENSATION
$185K
AGE
66
TENURE
5.7 yrs

Bill Green

TITLE
Director
COMPENSATION
$185K
AGE
64
TENURE
2.1 yrs

André Hoffmann

TITLE
Director
COMPENSATION
$185K
AGE
60
TENURE
10.7 yrs

Mark Pulido

TITLE
Director
AGE
65
TENURE
0.7 yrs
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess Inovalon Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Inovalon Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Inovalon Holdings, Inc., a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company’s platform enables the assessment and enhancement of clinical and quality outcomes and financial performance. It serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. The company provides technology that supports approximately 500 healthcare organizations. Its platforms are informed by data pertaining to approximately 932,000 physicians; 455,000 clinical facilities; and approximately 240 million individuals and 37 billion medical events. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland.

Details
Name: Inovalon Holdings, Inc.
IOV
Exchange: DB
Founded: 1998
$1,383,777,895
152,663,843
Website: http://www.inovalon.com
Address: Inovalon Holdings, Inc.
4321 Collington Road,
Bowie,
Maryland, 20716,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS INOV Class A Common Stock Nasdaq Global Select US USD 12. Feb 2015
DB IOV Class A Common Stock Deutsche Boerse AG DE EUR 12. Feb 2015
Number of employees
Current staff
Staff numbers
2,119
Inovalon Holdings employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/09/22 18:42
End of day share price update: 2018/09/21 00:00
Last estimates confirmation: 2018/09/05
Last earnings filing: 2018/08/01
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.